Medpace price target raised to $450 from $400 at Jefferies

Jefferies raised the firm’s price target on Medpace (MEDP) to $450 from $400 and keeps a Hold rating on the shares. Biotech funding was stronger in the last three months and bookings improved across the contract research organization industry, the analyst tells investors in a research note. However, Jefferies believes recent demand signals “are still equally mixed.”